MAPT and Alzheimer disease: In addition, ApoE4 also directly affected neuropathological markers of AD compared to ApoE3: it enhanced tau protein aggregation and impaired Aβ uptake and aggregation (Huang et al., 2017; Shi Y. et al., 2017; Lin et al., 2018; Chen et al., 2021).